

Ref no: 206140716
From: Commercial
Date: 14/07/16
Subject: Treatment for carcinoma and melanoma

REQUEST

The number of patients with NON SMALL CELL LUNG CARCINOMA (Stage IIIB/Stage IV) treated in the last 6 months with the following:

Afatinib (Giotrif)
Ceritinib (Zykadia)
Crizotinib (Xalkori)
Erlotinib (Tarceva)
Gefitinib (Iressa)
Pemetrexed (Alimta)
Nivolumab (Opdivo)
Nintedanib (Vargatef)

The number of patients with METASTATIC MELANOMA Stage IV (advanced or metastatic), treated in the last 6 months with the following:

Ipilimumab (Yervoy)
Nivolumab (Opdivo)
Ipilimumab AND Nivolumab
Pembrolizumab (Keytruda)
Vemurafenib (Zelboraf)
Vemurafenib AND Cobimetinib
Dabrafenib (Taflinar)
Trametinib (Mekinist)
Dabrafenib AND trametinib
Dacarbazine (DTIC)

RESPONSE

Unfortunately the Somerset Cancer Register nor the Trust's pharmacy system, records the specific drug name for each patient.